DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo

3.42 -0.15 (-4.20%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ARNA $3.42 -4.20%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.57
Previous Close $3.57
Daily Range $3.40 - $3.60
52-Week Range $3.26 - $7.97
Market Cap $752.8M
P/E Ratio -14.88
Dividend (Yield) $0.00 (0.0%)
Volume 4,423,360
Average Daily Volume 3,306,869
Current FY EPS -$0.26





Arena Pharmaceuticals, Inc. (ARNA) Description

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Website:

News & Commentary

The Newest FDA-Approved Obesity Drug Is Also the Oldest

Novo Nordisk gains FDA approval for Saxenda, which is already approved as an obesity treatment called Victoza.

Is Vivus Headed Towards An Unfortunate Ending?

3 Stocks Poised for Eye-Popping Gains in 2015

Gilead Sciences, Orexigen Therapeutics, and Prothena Corp. are all poised to have a huge 2015. Here's what investors need to know.

First Week Of March 2015 Options Trading For Arena Pharmaceuticals

Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock

Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog

3 Biotech Stocks I Don't Want for Christmas

I’d prefer coal in my stocking to these three troubled biotech stocks.

Novo Nordisk Enters Anti-Obesity Space With New FDA Approval

Contrave Prescriptions Still Rising In A Down Week

Orexigen - Contrave Script Numbers Remain Impressive

See More ARNA News...

ARNA's Top Competitors

ARNA $3.42 (-4.20%)
Current stock: ARNA
AMGN $163.46 (1.74%)
Current stock: AMGN
GILD $93.79 (2.74%)
Current stock: GILD
BIIB $342.40 (0.44%)
Current stock: BIIB